Cantor Fitzgerald Analysts Give Valeant Pharmaceuticals Intl (VRX) a $25.00 Price Target
Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other equities analysts have also commented on the stock. Mizuho increased their price target on shares of Valeant Pharmaceuticals Intl from $7.00 to $10.00 and gave the stock an underperform rating in a report on Friday, December 15th. JPMorgan Chase & Co. lowered shares of Valeant Pharmaceuticals Intl from a neutral rating to an underweight rating and set a $12.00 price target on the stock. in a report on Thursday, December 14th. ValuEngine raised shares of Valeant Pharmaceuticals Intl from a hold rating to a buy rating in a report on Tuesday, December 12th. Vetr raised shares of Valeant Pharmaceuticals Intl from a buy rating to a strong-buy rating and set a $19.72 target price on the stock in a report on Tuesday, December 5th. Finally, Deutsche Bank set a $18.00 target price on shares of Valeant Pharmaceuticals Intl and gave the company a hold rating in a report on Sunday, December 3rd. Six investment analysts have rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $17.83.
Valeant Pharmaceuticals Intl (NYSE VRX) traded up $0.04 during midday trading on Monday, reaching $23.05. 15,323,434 shares of the company’s stock traded hands, compared to its average volume of 16,878,611. The stock has a market cap of $8,030.00, a PE ratio of 5.91, a PEG ratio of 0.65 and a beta of -0.22. Valeant Pharmaceuticals Intl has a fifty-two week low of $8.31 and a fifty-two week high of $23.47. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84.
In other news, Director John Paulson purchased 344,216 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.87% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Riggs Asset Managment Co. Inc. boosted its position in Valeant Pharmaceuticals Intl by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 4,512 shares during the period. Cetera Investment Advisers purchased a new stake in Valeant Pharmaceuticals Intl during the 2nd quarter valued at $192,000. Harbour Capital Advisors LLC purchased a new stake in Valeant Pharmaceuticals Intl during the 3rd quarter valued at $224,000. American Century Companies Inc. purchased a new stake in Valeant Pharmaceuticals Intl during the 3rd quarter valued at $238,000. Finally, Moors & Cabot Inc. boosted its position in Valeant Pharmaceuticals Intl by 32.3% during the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock valued at $267,000 after buying an additional 3,725 shares during the period. 49.45% of the stock is owned by institutional investors and hedge funds.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with Analyst Ratings Network's FREE daily email newsletter.